Boundless Bio Inc (BOLD) Stock Price, Quote & News

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It also develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 dem...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 766 9912

Website: boundlessbio.com

Address:

10955 Alexandria Way, Suite 100, San Diego, United States

NVDAMillionaire Sep. 9 at 12:24 PM

$BOLD Really good write-up that perfectly summarizes BOLD's present situation. So if you want to bring your BOLD knowledge up to date or just discover BOLD, this is required reading. https://beyondspx.com/quote/BOLD/analysis/unlocking-cancer-s-code-boundless-bio-s-ecdna-strategy-and-extended-runway-bold

0 · Reply

MorenitaScorp Sep. 2 at 12:43 PM

$BOLD ⌚️

0 · Reply

topstockalerts Sep. 2 at 11:03 AM

Pre Market Top Gainers PT2 $MLYS $FLGC $BOLD $TIXT $CYCU

0 · Reply

habesha_kingtchalla Aug. 28 at 2:01 AM

$BOLD

0 · Reply

ZenithZephyr Aug. 23 at 7:50 AM

$BOLD Boundless Bio Inc is a clinical stage oncology company with novel target approach

0 · Reply

JarvisFlow Aug. 11 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Boundless Bio ( $BOLD ), setting the rating to Buy with a target price of 5 → 4.

0 · Reply

Galtor Jul. 29 at 11:08 PM

$BOLD how is this not pulling a $BHVN type run like they had a couple years ago??

0 · Reply

Galtor Jul. 23 at 11:38 PM

$BOLD now begins the steady climb up

0 · Reply

Dirk1969 Jul. 19 at 6:26 AM

$BOLD https://www.fiercebiotech.com/biotech/boundless-bio-lays-33-staff-lead-program-stumbles

1 · Reply

soopabox Jul. 18 at 2:41 PM

$BOLD On the 3 month chart a very vague handle of a cup and handle seems to be forming. It looks more like a skillet instead of a cup. Not getting excited about it until -or- if it breaks 1.20 with volume.

1 · Reply

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Jun 5, 2025, 4:58 PM EDT - 3 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 23, 2025, 4:01 PM EDT - 4 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 9, 2025, 7:00 AM EDT - 4 months ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Apr 3, 2025, 7:00 AM EDT - 5 months ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 6 months ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 26, 2025, 7:00 AM EST - 7 months ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 3, 2025, 10:00 AM EST - 8 months ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Dec 12, 2024, 4:01 PM EST - 9 months ago

Boundless Bio Announces Pipeline and Leadership Updates

Nov 25, 2024, 7:00 AM EST - 10 months ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 7, 2024, 4:01 PM EST - 11 months ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 7:00 AM EST - 11 months ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 13, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 6, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

MMA MNDR NTCL NTHI ROTR UBXG WAY

Mar 27, 2024, 6:55 PM EDT - 1 year ago

Boundless Bio Announces Pricing of Initial Public Offering

Mar 23, 2024, 12:20 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Tech IPOs Pop As End Of March Approaches

ALAB AUNA INTJ MNDR RDDT

Mar 12, 2024, 4:16 PM EDT - 1 year ago

Boundless Bio Starts $100 Million U.S. IPO Plan

NVDAMillionaire Sep. 9 at 12:24 PM

0 · Reply

MorenitaScorp Sep. 2 at 12:43 PM

$BOLD ⌚️

0 · Reply

topstockalerts Sep. 2 at 11:03 AM

Pre Market Top Gainers PT2 $MLYS $FLGC $BOLD $TIXT $CYCU

0 · Reply

habesha_kingtchalla Aug. 28 at 2:01 AM

$BOLD

0 · Reply

ZenithZephyr Aug. 23 at 7:50 AM

$BOLD Boundless Bio Inc is a clinical stage oncology company with novel target approach

0 · Reply

JarvisFlow Aug. 11 at 11:00 AM

HC Wainwright & Co. has adjusted their stance on Boundless Bio ( $BOLD ), setting the rating to Buy with a target price of 5 → 4.

0 · Reply

Galtor Jul. 29 at 11:08 PM

$BOLD how is this not pulling a $BHVN type run like they had a couple years ago??

0 · Reply

Galtor Jul. 23 at 11:38 PM

$BOLD now begins the steady climb up

0 · Reply

Dirk1969 Jul. 19 at 6:26 AM

$BOLD https://www.fiercebiotech.com/biotech/boundless-bio-lays-33-staff-lead-program-stumbles

1 · Reply

soopabox Jul. 18 at 2:41 PM

1 · Reply

AceDeBase Jul. 2 at 7:05 AM

$BOLD All tanks FULL. NOwhere to put ng

0 · Reply

AceDeBase Jul. 2 at 6:56 AM

$BOLD SWITCH TO. TIMBER AS in. T i m b e r. Down

0 · Reply

Galtor Jun. 29 at 12:26 AM

$BOLD way oversold now

0 · Reply

BioRich Jun. 12 at 3:07 PM

$BOLD Loaded more to this one. Been strong on it in the past and see no reason not to be strong looking forward. Best of luck to longs believing in BOLD. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital

2 · Reply

Zaga64 Jun. 11 at 4:33 PM

$BOLD Cash, cash equivalents, and short-term investments totaled $138.3 million as of March 31, 2025. Shares Outstanding 22.39M Float 14.28M

0 · Reply

Galtor Jun. 11 at 1:08 AM

$BOLD high volume day that closes red near support. Could be the sign of a reversal.

0 · Reply

Rohtan Jun. 9 at 11:12 PM

$BOLD this is done for a while. May fall below $1

0 · Reply

JarvisFlow Jun. 2 at 11:00 AM

HC Wainwright & Co. has updated their rating for Boundless Bio ( $BOLD ) to Buy with a price target of 5.

0 · Reply

tradersunion353 Jun. 1 at 3:47 AM

$BOLD Dilution and Reverse split coming soon

1 · Reply

buythedipsbro May. 30 at 4:25 PM

$BOLD too cheap indeed. assuming they b urn 40-50m a yr at current rate, by next year wed still have around 78-88m cash, at 25m market cap, lol

0 · Reply

Stmkr May. 30 at 2:02 PM

$BOLD Cash runway into 2028 $128 million cash as of Mar 2025 Trading at $25M... First 2 assets failed but now they are trying a combination of the 2 assets... Cheap for a reason. But maybe too cheap?

0 · Reply

Qtradesstocks May. 30 at 12:17 PM

$BOLD taking an L 🥴 catalyst not expected till next year. At 50cent or so a share I’d consider buying back

0 · Reply

Market Cap	25.74M
Revenue (ttm)	0.00
Net Income (ttm)	-65.36M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	60,500
Avg Vol	85,984
Day's Range	N/A - N/A
Shares Out	22.39M
Stochastic %K	71%
Beta	-1.22
Analysts	Sell
Price Target	$3.50